← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSTIMULANTS › IMMUNOSTIMULANTS › Colony stimulating factors
lipegfilgrastim
L03AA14
Forms & Strengths
- 6 mg/0.6 mL solution for injection in pre-filled syringe
Adult Dosing
- 6 mg subcutaneously once per chemotherapy cycle
- Administer at least 24 hours after chemotherapy
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Prevention of neutropenia in patients receiving chemotherapy
- Reducing the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy
Mechanism of Action
- Long-acting recombinant human granulocyte colony-stimulating factor (G-CSF) analog
- Stimulates production of neutrophils in bone marrow
- Increases phagocytic activity of mature neutrophils
Contraindications
- Hypersensitivity to lipegfilgrastim or filgrastim
- Sickle cell disease with a history of splenic rupture
Adverse Reactions
- Bone pain
- Musculoskeletal pain
- Increased liver enzymes
- Allergic reactions
- Sickle cell crisis
Drug Interactions
- No formal drug interaction studies have been conducted
- Caution with lithium, as it can potentiate the release of neutrophils
Curated Content: Needs Vetting Before Put to Clinical Use